Myelodysplasia paranoia: Iron as the new radon

Leukemia Research

Volumn 33, Issue 9, 2009, Pages 1158-1163

  Steensma, David P ^a  

^a MAYO CLINIC   (United States)

Author keywords

Deferasirox; Iron chelation; Myelodysplastic syndromes; Red blood cell transfusion; T2* MRI

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; FERRITIN; IRON; PAROXETINE; PRAMIPEXOLE; PREGABALIN; RADON;

AGRANULOCYTOSIS; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ANXIETY DISORDER; ARTICLE; BETA THALASSEMIA; CHELATION THERAPY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; FERRITIN BLOOD LEVEL; FIBROMYALGIA; HUMAN; IRON CHELATION; IRON OVERLOAD; KIDNEY FAILURE; LIVER FAILURE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RESTLESS LEGS SYNDROME; SIDE EFFECT;

EID: 67549104444     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.10.017     Document Type: Note

References (62)

1. Bennett JM, List AF. For the Myelodysplastic Syndromes Foundation I. Disparities in criteria for initiating chelation therapy for iron overload in patients with myelodysplastic syndromes (MDS). ASH Annual Meeting Abstracts. November 16, 2005;106(11):2535.
2. Tefferi A. Iron chelation therapy for myelodysplastic syndrome: if and when. Mayo Clin Proc 81 February (2) (2006) 197-198
3. Stone R. Elevated serum ferritin in patients with a myelodysplastic syndrome: how much of a problem?. Am J Hematol 83 August (8) (2008) 609-610
4. Gattermann N. Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Int J Hematol 88 July (1) (2008) 24-29
5. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 March (6) (1997) 2079-2088
6. Malcovati L., Porta M.G., Pascutto C., Invernizzi R., Boni M., Travaglino E., et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 23 October (30) (2005) 7594-7603
7. Armand P., Kim H.T., Cutler C.S., Ho V.T., Koreth J., Alyea E.P., et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 109 May (10) (2007) 4586-4588
8. Mahindra A., Sobecks R., Rybicki L., Brown S., Pohlman B., Kalaycio M., et al. Abstract: elevated ferritin is associated with poorer survival following nonablative allogeneic transplantation. Blood 110 11 (2007)
9. Mahindra A., Bolwell B., Sobecks R., Rybicki L., Brown S., Pohlman B., et al. Abstract: prognostic impact of elevated pretransplant serum ferritin in allogeneic hematopoietic stem cell transplantation. Blood 110 11 (2007)
10. Park I.H., Kim Y., Kim J.S., Cheong J.W., Song J.W., and Min Y.H. Transfusion-associated iron overload as a predictive factor for poor stem cell mobilization in patients with haematological malignancies. Transfus Med 18 April (2) (2008) 97-103
11. Malcovati L. Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. Leukemia Res 31 December (Suppl. 3) (2007) S2-S6
12. Cazzola M., and Malcovati L. Myelodysplastic syndromes-coping with ineffective hematopoiesis. N Engl J Med 352 February (6) (2005) 536-538
13. Malcovati L., Germing U., Kuendgen A., Della Porta M.G., Pascutto C., Invernizzi R., et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25 August (23) (2007) 3503-3510
14. Olivieri N.F., Nathan D.G., MacMillan J.H., Wayne A.S., Liu P.P., McGee A., et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 331 September (9) (1994) 574-578
15. Brittenham G.M., Griffith P.M., Nienhuis A.W., McLaren C.E., Young N.S., Tucker E.E., et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 331 September (9) (1994) 567-573
16. Modell B., Khan M., and Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 355 June (9220) (2000) 2051-2052
17. Tehranchi R., Invernizzi R., Grandien A., Zhivotovsky B., Fadeel B., Forsblom A.M., et al. Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes. Blood 106 July (1) (2005) 247-253
18. Beris P., Samii K., Darbellay R., Zoumbos N., Tsoplou P., Kourakli A., et al. Iron overload in patients with sideroblastic anaemia is not related to the presence of the haemochromatosis Cys282Tyr and His63Asp mutations. Br J Haematol 104 January (1) (1999) 97-99
19. Nearman Z.P., Szpurka H., Serio B., Warshawksy I., Theil K., Lichtin A., et al. Hemochromatosis-associated gene mutations in patients with myelodysplastic syndromes with refractory anemia with ringed sideroblasts. Am J Hematol 82 December (12) (2007) 1076-1079
20. Varkonyi J., Tarkovacs G., Karadi I., Andrikovics H., Varga F., Demeter J., et al. High incidence of hemochromatosis gene mutations in the myelodysplastic syndrome: the Budapest Study on 50 patients. Acta Haematol 109 2 (2003) 64-67
21. Gattermann N., Aul C., and Schneider W. Two types of acquired idiopathic sideroblastic anaemia (AISA). Br J Haematol 74 January (1) (1990) 45-52
22. Dawson D.W., Fish D.I., and Shackleton P. The accuracy and clinical interpretation of serum ferritin assays. Clin Lab Haematol 14 1 (1992) 47-52
23. Nielsen P., Gunther U., Durken M., Fischer R., and Dullmann J. Serum ferritin iron in iron overload and liver damage: correlation to body iron stores and diagnostic relevance. J Lab Clin Med 135 May (5) (2000) 413-418
24. Fischer R., Piga A., Harmatz P., and Nielsen P. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry. Ann NY Acad Sci 1054 (2005) 350-357
25. St Pierre T.G., Clark P.R., Chua-anusorn W., Fleming A.J., Jeffrey G.P., Olynyk J.K., et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 105 January (2) (2005) 855-861
26. Chacko J., Pennell D.J., Tanner M.A., Hamblin T.J., Wonke B., Levy T., et al. Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions. Br J Haematol 138 September (5) (2007) 587-593
27. Konen E., Ghoti H., Goitein O., Winder A., Kushnir T., Eshet Y., et al. No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2 technique. Am J Hematol 82 November (11) (2007) 1013-1016
28. Di Tucci A.A., Matta G., Deplano S., Gabbas A., Depau C., Derudas D., et al. Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias. Haematologica 93 September (9) (2008) 1385-1388
29. List A., Baer M., Steensma D., Raza A., Esposito J., Virkus J., et al. Abstract 1470: deferasirox (ICL670; Exjade) reduces serum ferritin (SF) and labile plasma iron (LPI) in patients with myelodysplastic syndromes (MDS). Blood 110 11 (2007)
30. Metzgeroth G., Dinter D., Schultheis B., Dorn-Beineke A., Lutz K., Leismann O., et al. Deferasirox in MDS patients with transfusion-caused iron overload-a phase-II study. Ann Hematol (2008)
31. Greenberg PL, Schiffer CA, Koller CA, Kang B, Decker J, Paley C. Liver Iron concentration measurements using MRI R2 in MDS patients in a deferasirox (Exjade(R), ICL670) phase II study. ASH Annual Meeting Abstracts. November 16, 2006;108(11):4846.
32. Chee C.E., Steensma D.P., Wu W., Hanson C.A., and Tefferi A. Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts. Am J Hematol 83 August (8) (2008) 611-613
33. Leitch H.A. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy. Leukemia Res 31 December (Suppl. 3) (2007) S7-9
34. Rose C, Brechignac S, Vassilief D, Beyne-Rauzy O, Stamatoullas A, Larbaa D, et al. Positive impact of iron chelation therapy (CT) on survival in regularly transfused mds patients. A Prospective Analysis by the GFM. ASH Annual Meeting Abstracts. November 16, 2007;110(11):249.
35. Leitch HA, Wong DHC, Leger CS, Ramadan KM, Rollins MD, Barnett MJ, et al. Improved leukemia-free and overall survival in patients with myelodysplastic syndrome receiving iron chelation therapy: a subgroup analysis. ASH Annual Meeting Abstracts. November 16, 2007;110(11):1469.
36. Lesnefsky E.J. Tissue iron overload and mechanisms of iron-catalyzed oxidative injury. Adv Exp Med Biol 366 (1994) 129-146
37. Kantarjian H., O'Brien S., Ravandi F., Cortes J., Shan J., Bennett J.M., et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 113 September (6) (2008) 1351-1361
38. Greenberg PL, NCCNPanel. National Comprehensive Cancer Network (NCCN) Clinical Practic Guidelines in Oncology: Myelodysplastic Syndromes (v1. 2009). 2009 [cited 2008 October 11]. Available from: http://www.nccn.org/professionals/physician_gls/PDF/mds.pdf
39. Alessandrino E.P., Amadori S., Barosi G., Cazzola M., Grossi A., Liberato L.N., et al. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes: a statement from the Italian society of hematology. Haematologica 87 December (12) (2002) 1286-1306
40. Bowen D., Culligan D., Jowitt S., Kelsey S., Mufti G., Oscier D., et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 120 January (2) (2003) 187-200
41. Bennett J.M. Consensus statement on iron overload in myelodysplastic syndromes. Am J Haematol (2008)
42. Suzuki T., Tomonaga M., Miyazaki Y., Nakao S., Ohyashiki K., Matsumura I., et al. Japanese epidemiological survey with consensus statement on Japanese guidelines for treatment of iron overload in bone marrow failure syndromes. Int J Hematol 88 July (1) (2008) 30-35
43. Valent P., Krieger O., Stauder R., Wimazal F., Nosslinger T., Sperr W.R., et al. Iron overload in myelodysplastic syndromes (MDS)-diagnosis, management, and response criteria: a proposal of the Austrian MDS platform. Eur J Clin Invest 38 March (3) (2008) 143-149
44. Mittelman M., Lugassy G., Merkel D., Tamary H., Sarid N., Rachmilewitz E., et al. Iron chelation therapy in patients with myelodysplastic syndromes: consensus conference guidelines. Isr Med Assoc J 10 May (5) (2008) 374-376
45. Merson L., and Olivier N. Orally active iron chelators. Blood Rev 16 June (2) (2002) 127-134
46. Vichinsky E., Pakbaz Z., Onyekwere O., Porter J., Swerdlow P., Coates T., et al. Patient-reported outcomes of deferasirox (Exjade ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial. Acta Haematol 119 3 (2008) 133-141
47. Cappellini M.D., Bejaoui M., Agaoglu L., Porter J., Coates T., Jeng M., et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clin Therap 29 May (5) (2007) 909-917
48. US Census Bureau press release, 26 August 2008. Household Income Rises, Poverty Rate Unchanged, Number of Uninsured Down. Available from: http://www.census.gov/Press-Release/www/releases/archives/income_wealth/012528.html. Accessed 16 October 2008.
49. Delea T.E., Sofrygin O., Thomas S.K., Baladi J.F., Phatak P.D., and Coates T.D. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective. PharmacoEconomics 25 4 (2007) 329-342
50. Karnon J., Tolley K., Oyee J., Jewitt K., Ossa D., and Akehurst R. Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom. Curr Med Res Opin 24 June (6) (2008) 1609-1621
51. Kontoghiorghes G.J. Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox. Hemoglobin 32 1-2 (2008) 1-15
52. Kontoghiorghes G.J. Deferasirox: uncertain future following renal failure fatalities, agranulocytosis and other toxicities. Exp Opin Drug Saf 6 May (3) (2007) 235-239
53. Spaeth M. Is pregabalin a safe and effective treatment for patients with fibromyalgia?. Nat Clin Pract Rheumatol 4 October (10) (2008) 514-515
54. Woloshin S., and Schwartz L.M. Giving legs to restless legs: a case study of how the media helps make people sick. PLoS Med 3 April (4) (2006) e170
55. Healy D. Have drug companies hyped social anxiety disorder to increase sales. Yes: marketing hinders discovery of long-term solutions. West J Med 175 December (6) (2001) 364
56. Harley N.H., Chittaporn P., Heikkinen M.S., Meyers O.A., and Robbins E.S. Radon carcinogenesis: risk data and cellular hits. Radiat Prot Dosim 130 1 (2008) 107-109
57. Andrews N.C. Forging a field: the golden age of iron biology. Blood 112 July (2) (2008) 219-230
58. Steensma D.P. DNA damage and repair mechanisms. In: Karp J.E. (Ed). Acute myelogenous leukemia (2007), Humana, Totowa, NJ
59. Krewski D., Lubin J.H., Zielinski J.M., Alavanja M., Catalan V.S., Field R.W., et al. A combined analysis of North American case-control studies of residential radon and lung cancer. J Toxicol Environ Health 69 April (7) (2006) 533-597
60. Luckey T.D. Radiation hormesis: the good, the bad, and the ugly. Dose Response 4 3 (2006) 169-190
61. Auerbach M., and Ballard H. Intravenous iron in oncology. J Natl Compr Canc Netw 6 July (6) (2008) 585-592 [quiz 92]
62. Garcia-Manero G., Shan J., Faderl S., Cortes J., Ravandi F., Borthakur G., et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 22 March (3) (2008) 538-543